Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 2/20 | 0.41 |
| ▸ | CCR3 | P51677 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | GPR6 | P46095 | 1/20 | 0.39 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.38 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5886956 | 0.89 | CTNNB1 (0.44) | PPARGMAPK8CTNNB1TCF7L2NAMPT | |
| SCHEMBL5887179 | 0.89 | MEN1 (0.50) | MEN1KMT2ASCN9AMCHR1 | |
| SCHEMBL5886769 | 0.89 | PPARG (0.43) | PPARGMEN1KMT2ACTNNB1TCF7L2 | |
| SCHEMBL5886999 | 0.88 | KMT2A (0.41) | PPARGKMT2ACTNNB1TCF7L2NAMPT | |
| SCHEMBL5887369 | 0.87 | KDM4E (0.41) | PPARGMEN1KMT2ATRPV1KDM4E | |
| SCHEMBL5887280 | 0.87 | CTNNB1 (0.40) | PPARGMEN1KMT2ACTNNB1TCF7L2 | |
| SCHEMBL5886836 | 0.86 | KLKB1 (0.40) | PPARGMEN1KMT2AMCHR1CTNNB1 | |
| SCHEMBL5887137 | 0.86 | CTNNB1 (0.41) | PPARGGPR6CTNNB1TCF7L2NAMPT | |
| SCHEMBL5887034 | 0.86 | NAMPT (0.39) | PPARGMEN1KMT2ACTNNB1TCF7L2 | |
| SCHEMBL5886742 | 0.86 | CTNNB1 (0.43) | PPARGMEN1KMT2AKDM4ECTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | claimed |
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | PHARMACIA ITALIA S.P.A. | 2004-01-15 | — | — | US | claimed |
| US-7019002-B2 | Substituted on 8th position with benzoic acid, ester or amide groups; anticancer agents | PHARMACIA & UPJOHN, S.P.A. (IT) | 2006-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040009993-A1 | Pyridopyrimidinones derivatives as telomerase inhibitors | TERT, TERF2, TERF2IP | PPARG 3749/4885CCR3 4254/4885MEN1 2183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.